Literature DB >> 18624896

Clinical features and survival in Chinese patients with hepatitis B e antigen-negative hepatitis B virus-related cirrhosis.

Hui Ma1, Lai Wei, Fang Guo, Sainan Zhu, Yan Sun, Hao Wang.   

Abstract

AIM: To compare the clinical features of hepatitis B e antigen (HBeAg)-negative and HBeAg-positive cirrhosis, and to define the survival and prognostic indicators of Chinese HBeAg-negative hepatitis B virus (HBV)-related cirrhosis.
METHODS: Two hundred and seventeen patients with chronic hepatitis B cirrhosis were studied. Survival was calculated using the Kaplan-Meier method. Proportional hazards Cox regression procedure was used to identify independent predictors of survival. The relationship between HBV-DNA viral load and prognosis was also investigated.
RESULTS: The mean follow-up time was 35 months (3-47 months). HBeAg-negative liver cirrhosis patients comprised the greatest number of cirrhosis patients. Median alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, median total leukocytes (WBC), hemoglobin (Hb), platelet (Plt) and HBV-DNA levels and the proportion of HBV-DNA > 10(5) copies/mL were lower in HBeAg-negative patients. There were fewer complications in patients treated with lamivudine than in other patients. Survival rates were significantly reduced in patients with HBeAg-negative cirrhosis (P = 0.0024). The baseline Child-Pugh scores and more than one decompensation during follow up were independent variables correlated with survival of HBeAg-negative liver cirrhosis patients (P = 0.006 and P = 0.001, respectively). The HBV-DNA viral load did not correlate with any complications or mortality rates of HBeAg-negative patients.
CONCLUSIONS: The clinical features of HBeAg-negative and -positive liver cirrhosis differ. Survival was significantly reduced for Chinese patients with HBeAg-negative than -positive cirrhosis. Factors contributing to the prognosis were baseline Child-Pugh scores and the presence of more than one decompensation during follow up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624896     DOI: 10.1111/j.1440-1746.2008.05499.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

1.  De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.

Authors:  Xiao-Hong Fan; Jian-Zhang Geng; Li-Fen Wang; Ying-Ying Zheng; Hai-Ying Lu; Jing Li; Xiao-Yuan Xu
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

Review 2.  Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.

Authors:  Bulent Baran
Journal:  World J Hepatol       Date:  2015-07-08

3.  Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis.

Authors:  Maja Thiele; Lise L Gluud; Emilie K Dahl; Aleksander Krag
Journal:  BMJ Open       Date:  2013-08-14       Impact factor: 2.692

Review 4.  Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses.

Authors:  Maja Thiele; Lise Lotte Gluud; Annette Dam Fialla; Emilie Kirstine Dahl; Aleksander Krag
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.